|Articles|May 1, 2008

Applied Clinical Trials

  • Applied Clinical Trials-05-01-2008
  • Volume 0
  • Issue 0

April Global News

The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received ?5 million from Spain's Agencia Espa?ola de Cooperaci?n Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.

April Global News

• The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received €5 million from Spain's Agencia Española de Cooperación Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.

Thailand's Public Health Minister Chaiya Sasomsap announced that Siriwat Thiptharadon, head of Thailand's Food and Drug Administration, was removed from his position and moved instead to an inactive post. Thiptharadon is known for establishing the former government's compulsory license program, which aimed to make drugs more affordable and is now vulnerable to a committee review under Sasomsap's orders. Chatree Banchuen was named secretary general of Thailand's FDA following Thiptharadon's departure, but resigned a week later citing that he was "uncomfortable with the politics."

Kampala, Uganda's Mulago Hospital, a 1500-bed facility affiliated with Makerere University, is the home of the first Health Volunteers Overseas (HVO; Washington, DC) hematology training program, created by HVO and the American Society of Hematology (Washington, DC). The program's purpose is to bolster the hematology training of clinicians, lab technicians, technologists, and students.

The University of Portsmouth (Hampshire, UK) is collaborating with brain tumor charity Brainstrust (Hampshire, UK) among others to create the UK's first dedicated laboratory-based brain tumor research center. Brain tumors are the most common form of cancer in people under 40 and the most common cause of death in children after accidents.

Articles in this issue

over 18 years ago

CDISC and HL7: aBRIDGed

over 18 years ago

Make Room for Change

over 18 years ago

Dissecting Adaptive Design

over 18 years ago

The Heavy Burden of Protocol Design

over 18 years ago

Trials Where They Make Sense

over 18 years ago

From the Ground Up

over 18 years ago

Business and People Update May 2008

Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.